Clinical Trials

MainTitle

CCR5-modified CD4+ T Cells for HIV Infection (TRAILBLAZER)

This study is currently recruiting participants. (see Contacts and Locations)

Verified July 2019 by Cheryl Smith, Case Western Reserve University

Sponsor
Case Western Reserve University

Collaborator
University of California, San Francisco
University of Cincinnati

Information provided by (Responsible Party)
Cheryl Smith, Case Western Reserve University

ClinicalTrials.gov Identifier
NCT03666871

First received: September 7, 2018
Last updated: July 22, 2019
Last Verified: July 2019
History of Changes
Purpose

Purpose

A Comparative Study of Autologous CD4+ T Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728 versus ex vivo Expanded Unmodified Autologous CD4+ T Cells in Treated HIV-1 Infected Subjects

Condition Intervention Phase
HIV Infections

Biological : SB-728-T
Biological : Expanded unmodified autologous CD4+ T cells
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Randomized, double-blind
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: T-Cell Reinfusion After Interfering With Lymphocyte Binding Location of AIDS Virus Through Zinc-finger-nuclease Elimination of CCR5 Receptors: The TRAILBLAZER Study

Further study details as provided by Cheryl Smith, Case Western Reserve University:

Primary Outcome Measures

  • Difference in the magnitude of change in IUPM from before infusion to 24 months after infusion, by the QVOA assay, between the two study arms. [ Time Frame: 24 months ]
    Difference in the magnitude of change in IUPM from before infusion to 24 months after infusion, by the QVOA assay, between the two study arms.
  • Difference in the proportion of participants who experience a grade ≥3 adverse event that is considered possibly, probably, or definitely related to study treatment between the two study arms. [ Time Frame: 24 months ]
    Difference in the proportion of participants who experience a grade ≥3 adverse event that is considered possibly, probably, or definitely related to study treatment between the two study arms.
  • Proportion of participants who experience a grade ≥3 adverse event that is considered possibly, probably, or definitely related to study treatment in each of the study arms. [ Time Frame: 24 months ]
    Proportion of participants who experience a grade ≥3 adverse event that is considered possibly, probably, or definitely related to study treatment in each of the study arms.
Secondary Outcome Measures:
  • Difference in the magnitude of change in IUPM from before infusion to 12 months after infusion, by the QVOA assay, between the two study arms [ Time Frame: 12 months ]
    Difference in the magnitude of change in IUPM from before infusion to 12 months after infusion, by the QVOA assay, between the two study arms
  • Change in the number of infectious units per million (IUPM) CD4+ T cells on the QVOA assay from the first leukapheresis visit to the month 12 visit. [ Time Frame: 12 months ]
    Change in the number of infectious units per million (IUPM) CD4+ T cells on the QVOA assay from the first leukapheresis visit to the month 12 visit.
  • Change in the number of infectious units per million (IUPM) CD4+ T cells on the QVOA assay from the first leukapheresis visit to the month 24 visit. [ Time Frame: 24 months ]
    Change in the number of infectious units per million (IUPM) CD4+ T cells on the QVOA assay from the first leukapheresis visit to the month 24 visit.
  • Peripheral CD4+ T cell count at each of the follow-up time points after infusion of ex vivo expanded CD4+ T cells in each study arm. [ Time Frame: 24 months ]
    Peripheral CD4+ T cell count at each of the follow-up time points after infusion of ex vivo expanded CD4+ T cells in each study arm.
  • Frequency of pentamer PCR-positive CD4+ T cells in peripheral blood at each of the follow-up time points after infusion of ex vivo expanded CD4+ T cells in the CCR5-modified study arm [ Time Frame: 24 months ]
    Frequency of pentamer PCR-positive CD4+ T cells in peripheral blood at each of the follow-up time points after infusion of ex vivo expanded CD4+ T cells in the CCR5-modified study arm
  • Frequency of pentamer PCR-positive CD4+ T cells in cell suspensions of rectal biopsy tissue [ Time Frame: 24 months ]
    Frequency of pentamer PCR-positive CD4+ T cells in cell suspensions of rectal biopsy tissue
  • Frequency of pentamer PCR-positive CD4+ T cells in cell suspensions of lymph node biopsy tissue [ Time Frame: 24 months ]
    Frequency of pentamer PCR-positive CD4+ T cells in cell suspensions of lymph node biopsy tissue
  • Frequency of pentamer PCR-positive CD4+ T cells in CSF [ Time Frame: 24 months ]
    Frequency of pentamer PCR-positive CD4+ T cells in CSF

Estimated Enrollment: 30
Study Start Date: June 12, 2019
Estimated Study Completion Date: February 28, 2024
Estimated Primary Completion Date: January 31, 2024 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
Experimental: Arm 1
Arm 1 (n=20) will be pretreated with cyclophosphamide 1 g/m2 and will receive a single intravenous infusion of 0.5 to 4x1010 ex vivo expanded autologous CD4+ T cells that have been transduced with a zinc finger nuclease designed to cleave CCR5.
Biological: SB-728-T

Autologous CD4+ T cells with ex vivo modification of the CCR5 gene by zinc finger nucleases

Active Comparator: Arm 2
Arm 2 (n=10) will be pretreated with cyclophosphamide 1 g/m2 and will receive a single intravenous infusion of 0.5 to 4x1010 ex vivo expanded autologous CD4+ T cells that have not been modified by zinc finger nucleases.
Biological: Expanded unmodified autologous CD4+ T cells

Autologous CD4+ T cells without ex vivo modification of the CCR5 gene by zinc finger nucleases

Detailed Description:

This is a randomized clinical trial comparing the effect of infusing expanded autologous CD4+ T cells with or without ex vivo modification of the CCR5 gene by zinc finger nucleases among HIV-infected patients with plasma HIV RNA levels <50 copies/mL for at least 48 weeks and CD4+ T cell counts greater than 350 cells/µL. The main hypothesis is that the infusion of modified CD4+ T cells will lead to a reduction in the size of the replication-competent HIV reservoir, as measured by the quantitative virus outgrowth assay (QVOA) that is greater than that resulting from infusion of unmodified CD4+ T cells. A total of 30 participants will be randomized to receive one infusion of 0.5 - 4 x 1010 ex vivo expanded autologous CD4+ T cells that have been either modified by transduction with a zinc finger nuclease designed to cleave CCR5 (arm 1, n=20) or unmodified (arm 2, n=10). All participants will be pre-treated with cyclophosphamide at a dose of 1 g/m2 before infusion. The primary outcome measure will be the change in the number of infectious units per million (IUPM) CD4+ T cells from study enrollment to 24 months after infusion of expanded CD4+ T cells.

Eligibility

Eligibility

Ages Eligible for Study: 18 Years to 70 Years  
Sexes Eligible for Study: All  
Accepts Healthy Volunteers: No  

Criteria

Inclusion Criteria:

    1. Written informed consent signed and dated by study subject.
    2. Men or women, including trans men or women, ≥18 and ≤70 years of age.
    3. For persons born male who have not been surgically sterilized, willingness to abstain from sexual activity that could result in conception for 90 days after the cyclophosphamide administration visit.
    4. HIV-1 infection, documented by any FDA-approved ELISA, EIA, or rapid antibody detection method, and confirmed by a second FDA-approved antibody-based test or by a positive FDA-approved HIV RNA detection assay.
    5. Adequate venous access for leukapheresis, as documented by standard clinical procedures at each site.
    6. The following laboratory values at screening:
        1. Absolute neutrophil count (ANC) > 1500/mm3
        2. Hemoglobin level ≥11 g/dL
        3. Platelet count ≥150,000/mm3
        4. Serum creatinine <1.5 mg/dL
        5. AST and ALT ≤2.5 times the upper limit of normal
        6. CD4+ T cell count > 350 cells/mm3
        7. HIV-1 RNA <50 copies/mL performed with an ultrasensitive HIV-1 PCR assay.
        8. Urine red blood cell (RBC) counts within the normal range used by each institution.
        9. INR ≤1.5 and PTT ≤2xULN
      1. Willing to comply with study-mandated evaluations.
      2. All subjects must have received combination antiretroviral therapy, and had plasma HIV RNA levels <50 copies/mL for at least 48 weeks. Subjects who had intermittent isolated episodes of detectable low-level viremia <500 copies RNA/mL flanked by values <50 copies/mL will remain eligible.
      3. On stable antiretroviral medication (no changes to treatment and no missed dose for >7 continuous days within 4 weeks of screening) and willing to continue on current antiretroviral therapy, unless a change is medically indicated, for the duration of the study. Note: Changes in formulation or a single within-class, single-agent change are permitted in the last 48 weeks but not within 12 weeks of study entry.


    Exclusion Criteria:
      1. Women and persons born female regardless of gender identity with childbearing potential. These participants are considered to be of childbearing potential if they are postmenarchial, have an intact uterus and at least one ovary, and have had at least one menstrual period in the past two years. Participants who have had a documented bilateral tubal ligation or a hysterectomy are not considered to be of childbearing potential.
      2. Previous gene therapy using an integrating vector.
      3. Allergy or hypersensitivity to study product excipients (human serum albumin, DMSO and Dextran 40).
      4. An antiretroviral regimen including maraviroc or any CCR5 inhibitor within 4 weeks prior to screening.
      5. Acute or chronic hepatitis C infection, defined as a positive plasma HCV RNA using any FDA-approved qualitative or quantitative test in a participant with a positive HCV antibody (HCV RNA testing is not required in participants with a negative HCV antibody) at screening. Participants who have completed a course of antiviral treatment for hepatitis C and have a confirmed plasma HCV RNA level below the limit of detection of the assay 12 weeks or longer after completion of therapy will be eligible.
      6. Acute or chronic hepatitis B infection, defined as a positive HBV surface antigen or a positive HBV DNA at screening.
      7. Any prior AIDS-defining condition within the past 5 years, except a history of CD4+ T cell count below 200 cells/mm3.
      8. Any active cancer or malignancy within the past 5 years, with the exception of successfully treated basal cell or squamous cell carcinoma of the skin or low-grade (0 or 1) anal or cervical intraepithelial neoplasia.
      9. Diagnosis of New York Heart Association (NYHA) grade 3 or 4 congestive heart failure, uncontrolled angina or uncontrolled arrhythmias.
      10. Corrected QT interval (QTc) >440 msec (by any formula).
      11. History or any features on physical examination indicative of a bleeding diathesis.
      12. Use of chronic corticosteroids, hydroxyurea, or immune-modulating agents (e.g., interleukin-2, interferon-alpha or gamma, granulocyte colony stimulating factors, etc.) within 30 days prior to screening or for any period extending to within 30 days prior to the planned infusion date.

      NOTE: Use of inhaled or topical steroids is not exclusionary.
    1. Breastfeeding or pregnant.
    2. Continued need for use of aspirin, warfarin or any other medication likely to affect platelet function or other aspects of blood coagulation significantly that cannot be held during the 7-day period prior to each of the leukapheresis procedures (or tissue/CSF sampling procedures for participating subjects) or that maintains biological activity beyond 7 days after discontinuation.
    3. Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements.
    4. Presence at screening of a serious and persistent illness requiring a new systemic treatment expected to last beyond the planned date of infusion and/or hospitalization within 30 days prior to the planned date of infusion.
    5. Planned or actual vaccine administration within 4 weeks prior to infusion.
    6. Intercurrent illness that in the opinion of the investigator may compromise the safety of the participant or interfere with study objectives.
    7. Any other condition that, in the opinion of the clinical investigator or sponsor, might compromise any aspect of this trial.

    For participants in the rectosigmoid biopsy program only:
    1. Major GI tract surgery within 45 days prior to the planned date of the baseline visit. Minor procedures involving only the anal canal such as condyloma ablations, hemorrhoidectomy, and anoscopy are permitted if cleared by the responsible surgeon.
    2. Abnormalities of the colorectal mucosa, or significant colorectal symptoms, which in the opinion of the clinician represent a contraindication to biopsy (including but not limited to presence of any unresolved injury, infectious or inflammatory condition of the local mucosa).

    For participants in the lymph node biopsy program at sites doing open biopsies only:
    1. BMI greater than 35 at screening.
    2. Anatomical condition that would prevent surgical access to either inguinal area, such as scar tissue, active skin condition affecting the area, or foreign material.
    3. Known hypersensitivity to local anesthetic agents.
    4. Contraindication for the use of epinephrine-containing local anesthetic formulations.
    5. Presence of pacemaker, implantable defibrillator, or other medical device thought to be susceptible to electromagnetic interference from electrocautery.

    For participants in the lymph node biopsy program at sites doing lymph node aspirates only:
    1. Anatomical condition that would prevent surgical access to either inguinal area, such as scar tissue, active skin condition affecting the area, or foreign material.
    2. Known hypersensitivity to local anesthetic agents.
    3. Contraindication for the use of epinephrine-containing local anesthetic formulations.

    For participants in the CSF sampling program only:
    1. Any condition that could prevent access to the subarachnoid space or obscure the anatomical landmarks for lumbar puncture, such as scar tissue, active skin condition affecting the area, or foreign material.
    2. Known hypersensitivity to local anesthetic agents.
    3. Known space-occupying central nervous system lesion, unless cleared by the treating
    physician.

contacts and locations

Contacts and Locations

Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT03666871

Contacts

Contact:   Cheryl Smith 216-844-8052 smith.cheryl@clevelandactu.org
Contact:   Jane Baum, BS 216-844-2546 baum.jane@clevelandactu.org

Locations

United States, Ohio
Case Clinical Research Site Recruiting
Cleveland, Ohio, United States, 44106
Contact: Cheryl Smith    216-844-8052    smith.cheryl@clevelandactu.org
Contact: Jane Baum    2168442546    baum.jane@clevelandactu.org
Principal Investigator: Benigno Rodriguez, MD

Sponsors and Collaborators

Case Western Reserve University
University of California, San Francisco
University of Cincinnati

Investigators

Principal Investigator: Benigno Rodriguez, MD Case Western Reserve University
More Information

More Information


Responsible Party: Cheryl Smith, Principal Investigator, Case Western Reserve University  
ClinicalTrials.gov Identifier: NCT03666871   History of Changes  
Other Study ID Numbers: TRAILBLAZER  
Study First Received: September 7, 2018  
Last Updated: July 22, 2019  
Individual Participant Data    
Plan to Share IPD: Undecided  

Studies a U.S. FDA-regulated Drug Product: Yes  
Studies a U.S. FDA-regulated Device Product: No  
Product Manufactured in and Exported from the U.S.: No  

Additional relevant MeSH terms:
Infection
HIV Infections
Acquired Immunodeficiency Syndrome

ClinicalTrials.gov processed this data on August 07, 2020
This information is provided by ClinicalTrials.gov.